SEARCH

SEARCH BY CITATION

Literature cited

  • Adams, J. M., and A. Strasser. 2008. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Research 68:40184021.
  • Alain, T., M. Kim, R. N. Johnston, S. Urbanski, A. E. Kossakowska, P. A. Forsyth, and P. W. Lee. 2006. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. British Journal of Cancer 95:10201027.
  • Boehm, T., J. Folkman, T. Browder, and M. S. O’Reilly. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404407.
  • Bursch, W., A. Ellinger, H. Kienzl, L. Torok, S. Pandey, M. Sikorska, R. Walker et al. 1996. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 17:15951607.
  • Cairns, J. 1975. Mutation selection and the natural history of cancer. Nature 255:197200.
  • Campbell, L. L., and K. Polyak. 2007. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6:23322338.
  • Carman, M. D., J. H. Schornagel, R. S. Rivest, S. Srimatkandada, C. S. Portlock, T. Duffy, and J. R. Bertino. 1984. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. Journal of Clinical Oncology 2:1620.
  • Carrick, S., S. Parker, N. Wilcken, D. Ghersi, M. Marzo, and J. Simes. 2005. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews:CD003372.
  • Cho, R. W., and M. F. Clarke. 2008. Recent advances in cancer stem cells. Current Opinion in Genetics and Development 18:4853.
  • Corley, D. A., K. Kerlikowske, R. Verma, and P. Buffler. 2003. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124:4756.
  • Costello, R. T., F. Mallet, B. Gaugler, D. Sainty, C. Arnoulet, J. A. Gastaut, and D. Olive. 2000. Human acute myeloid leukemia CD34 + /CD38-progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Research 60:44034411.
  • Crespi, B., and K. Summers. 2005. Evolutionary biology of cancer. Trends in Ecology and Evolution 20:545552.
  • Curt, G. A., D. N. Carney, K. H. Cowan, J. Jolivet, B. D. Bailey, J. C. Drake, K. S. Chien Song et al. 1983. Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. New England Journal of Medicine 308:199202.
  • Dang, L. H., C. Bettegowda, D. L. Huso, K. W. Kinzler, and B. Vogelstein. 2001. Combination bacteriolytic therapy for the treatment of experimental tumors. Proceedings of the National Academy of Science of the United State of America 98:1515515160.
  • Davis, J. J., and B. Fang. 2005. Oncolytic virotherapy for cancer treatment: challenges and solutions. The Journal of Gene Medicine 7:13801389.
  • Dean, M., T. Fojo, and S. Bates. 2005. Tumour stem cells and drug resistance. Nature Reviews. Cancer 5:275284.
  • Delbaldo, C., S. Michiels, N. Syz, J. C. Soria, T. Le Chevalier, and J. P. Pignon. 2004. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. The Journal of the American Medical Association 292:470484.
  • Dobrikova, E. Y., T. Broadt, J. Poiley-Nelson, X. Yang, G. Soman, S. Giardina, R. Harris et al. 2008. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Molecular Therapy 16:18651872.
  • Dowsett, M., N. J. Bundred, A. Decensi, R. C. Sainsbury, Y. Lu, M. J. Hills, F. J. Cohen et al. 2001. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiology, Biomarkers and Prevention 10:961966.
  • Engelman, J. A., K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman et al. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:10391043.
  • Espey, D. K., X. C. Wu, J. Swan, C. Wiggins, M. A. Jim, E. Ward, P. A. Wingo et al. 2007. Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer 110:21192152.
  • Etzioni, R., N. Urban, S. Ramsey, M. McIntosh, S. Schwartz, B. J. Reid, J. P. Radich et al. 2003. The case for early detection. Nature Reviews Cancer 3:110.
  • Ewald, P. W. 1999. Using evolution as a tool for controlling infectious diseases. In W. R.Trevathan, E. O.Smith, and J. J.McKenna, eds. Evolutionary Medicine, pp. 245270. Oxford University Press, Oxford.
  • Falconer, D. S., and T. F. C. Mackay. 1996. Introduction to Quantitative Genetics. Longmans Green, Harlow, Essex, UK.
  • Felsenstein, J.. 1985. Phylogenies and the comparative method. American Naturalist 125:115.
  • Frank, S. A., and M. A. Nowak. 2004. Problems of somatic mutation and cancer. Bioessays 26:291299.
  • Frumkin, D., A. Wasserstrom, S. Itzkovitz, T. Stern, A. Harmelin, R. Eilam, G. Rechavi et al. 2008. Cell lineage analysis of a mouse tumor. Cancer Research 68:59245931.
  • Galipeau, P. C., X. Li, P. L. Blount, C. C. Maley, C. A. Sanchez, R. D. Odze, K. Ayub et al. 2007. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Medicine 4:e67.
  • Gorre, M. E., M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P. N. Rao, and C. L. Sawyers. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876880.
  • Gottesman, M. M., T. Fojo, and S. E. Bates. 2002. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2:4858.
  • Greaves, M. 2007. Darwinian medicine: a case for cancer. Nature Reviews Cancer 7:213221.
  • Heng, H. H. 2007. Cancer genome sequencing: the challenges ahead. Bioessays 29:783794.
  • Hill, R. P. 2006. Identifying cancer stem cells in solid tumors: case not proven. Cancer Research 66:18911895; discussion 1890.
  • Hope, K. J., L. Jin, and J. E. Dick. 2004. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunology 5:738743.
  • Horns, R. C. Jr, W. J. Dower, and R. T. Schimke. 1984. Gene amplification in a leukemic patient treated with methotrexate. Journal of Clinical Oncology 2:27.
  • Kassen, R., and T. Bataillon. 2006. Distribution of fitness effects among beneficial mutations before selection in experimental populations of bacteria. Nature Genetics 38:484488.
  • Keller, L. K.. 1999. Levels of Selection in Evolution. Princeton University Press, Princeton, NJ.
  • Kobayashi, S., T. J. Boggon, T. Dayaram, P. A. Janne, O. Kocher, M. Meyerson, B. E. Johnson et al. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 352:786792.
  • Leroi, A. M., V. Koufopanou, and A. Burt. 2003. Cancer selection. Nature Reviews Cancer 3:226231.
  • Levin, B. R., and J. J. Bull. 2004. Population and evolutionary dynamics of phage therapy. Nature Reviews Microbiology 2:166173.
  • Levin, B. R., M. Lipsitch, and S. Bonhoeffer. 1999. Population biology, evolution, and infectious disease: convergence and synthesis. Science 283:806809.
  • Maley, C. C., and B. J. Reid. 2005. Natural selection in neoplastic progression of Barrett’s esophagus. Seminars in Cancer Biology 15:474483.
  • Maley, C. C., P. C. Galipeau, X. Li, C. A. Sanchez, T. G. Paulson, P. L. Blount, and B. J. Reid. 2004a. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Research 64:76297633.
  • Maley, C. C., P. C. Galipeau, X. Li, C. A. Sanchez, T. G. Paulson, and B. J. Reid. 2004b. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett’s esophagus. Cancer Research 64:34143427.
  • Maley, C. C., B. J. Reid, and S. Forrest. 2004c. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiology, Biomarkers and Prevention 13:13751384.
  • Maley, C. C., P. C. Galipeau, J. C. Finley, V. J. Wongsurawat, X. Li, C. A. Sanchez, T. G. Paulson et al. 2006. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature Genetics 38:468473.
  • Mandlekar, S., and A. N. Kong. 2001. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6:469477.
  • McBride, S. M. 2008. Natural selection’s challenge to the cancer stem cell hypothesis. Medical Hypotheses 71:471472.
  • Merlo, L. M., J. W. Pepper, B. J. Reid, and C. C. Maley. 2006. Cancer as an evolutionary and ecological process. Nature Reviews Cancer 6:924935.
  • Michor, F., Y. Iwasa, and M. A. Nowak. 2004. Dynamics of cancer progression. Nature Reviews Cancer 4:197205.
  • Moscow, J., C. S. Morrow, and C. H. Cowan. 2003. Drug resistance and its clinical circumvention. In D. W.Kufe, J. F.Holland, and E.Frei, eds. Cancer Medicine. pp. 711725. Ont., B. C. Decker, Hamilton.
  • Mullighan, C. G., L. A. Phillips, X. Su, J. Ma, C. B. Miller, S. A. Shurtleff, and J. R. Downing. 2008. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322:13771380.
  • Nowell, P. C. 1976. The clonal evolution of tumor cell populations. Science 194:2328.
  • O’Connor, R., M. Clynes, P. Dowling, N. O’Donovan, and L. O’Driscoll. 2007. Drug resistance in cancer – searching for mechanisms, markers and therapeutic agents. Expert Opinion on Drug Metabolism & Toxicology 3:805817.
  • Okasha, S. 2006. Evolution and the Levels of Selection. Clarendon Press, Oxford.
  • Orr, H. A.. 2005. The genetic theory of adaptation: a brief history. Nature Reviews Genetics 6:119127.
  • Paulson, T. G., L. Xu, C. Sanchez, P. L. Blount, K. Ayub, R. D. Odze, and B. J. Reid. 2006. Neosquamous epithelium does not typically arise from Barrett’s epithelium. Clinical Cancer Research 12:17011706.
  • Pepper, J. W. 2008a. Defeating pathogen drug resistance: guidance from evolutionary theory. Evolution 62:31853191.
  • Pepper, J. W. 2008b. Integrating evolutionary biology into cancer biology. http://www.santafe.edu/events/workshops/index.php/Integrating_Evolutionary_Theory_into_Cancer_Biology .
  • Pepper, J. W., K. Sprouffske, and C. C. Maley. 2007. Animal Cell Differentiation Patterns Suppress Somatic Evolution. PLoS Computational Biology 3:e250.
  • Polyak, K. 2007. Breast cancer stem cells: a case of mistaken identity? Stem Cell Reviews 3:107109.
  • Robertson, J. F. 2004. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treatment Reviews 30:695706.
  • Roche-Lestienne, C., and C. Preudhomme. 2003. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Seminars in Hematology 40:8082.
  • Rowe-Magnus, D. A., and D. Mazel. 2006. The Evolution of Antibiotic Resistance. In H. S.Seifert, and V. J.Dirita, eds. Evolution of Microbial Pathogens, pp. 221241. ASM Press, Washington, D.C.
  • Shah, N. P., B. J. Skaggs, S. Branford, T. P. Hughes, J. M. Nicoll, R. L. Paquette, and C. L. Sawyers. 2007. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. Journal of Clinical Investigation 117:25622569.
  • Shibata, D. 2008. Stem cells as common ancestors in a colorectal cancer ancestral tree. Current Opinion in Gastroenterology 24:5963.
  • Shipitsin, M., L. L. Campbell, P. Argani, S. Weremowicz, N. Bloushtain-Qimron, J. Yao, T. Nikolskaya et al. 2007. Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259273.
  • Stearns, S. C., and J. C. Koella. 2008. Evolution in Health and Disease. Oxford University Press, Oxford.
  • Taplin, M. E., G. J. Bubley, Y. J. Ko, E. J. Small, M. Upton, B. Rajeshkumar, and S. P. Balk. 1999. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Research 59:25112515.
  • Trent, J. M., R. N. Buick, S. Olson, R. C. Horns Jr, and R. T. Schimke. 1984. Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma. Journal of Clinical Oncology 2:815.
  • Vaughan, T. L., L. M. Dong, P. L. Blount, K. Ayub, R. D. Odze, C. A. Sanchez, P. S. Rabinovitch et al. 2005. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. The Lancet Oncology 6:945952.
  • Vincent, T. L., and J. S. Brown. 2005. Evolutionary Game Theory. Cambridge University Press, Cambridge.
  • Vincent, T. L. and R. A. Gatenby 2008. An evolutionary model for initiation, promotion, and progression in carcinogenesis. International Journal of Oncology 31(4):729737.
  • Visakorpi, T., E. Hyytinen, P. Koivisto, M. Tanner, R. Keinanen, C. Palmberg, A. Palotie et al. 1995. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 9:401406.
  • Visvader, J. E., and G. J. Lindeman. 2008. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Review Cancer 8:755768.
  • Wang, J. C. 2007. Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm. Cell Stem Cell 1:497501.
  • Wang, T. L., L. A. Diaz Jr, K. Romans, A. Bardelli, S. Saha, G. Galizia, M. Choti et al. 2004. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proceedings of the National Academy of Sciences of the United States of America 101:30893094.